Intra-Cellular Therapies Inc (NASDAQ:ITCI) – Equities researchers at Svb Leerink boosted their FY2019 earnings estimates for shares of Intra-Cellular Therapies in a note issued to investors on Tuesday, November 5th. Svb Leerink analyst M. Goodman now anticipates that the biopharmaceutical company will post earnings per share of ($3.10) for the year, up from their previous estimate of ($3.75). Svb Leerink also issued estimates for Intra-Cellular Therapies’ Q4 2019 earnings at ($1.03) EPS, FY2020 earnings at ($3.59) EPS, FY2021 earnings at ($2.33) EPS, FY2022 earnings at ($0.15) EPS and FY2023 earnings at $2.63 EPS.
Intra-Cellular Therapies (NASDAQ:ITCI) last posted its earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.17.
A number of other research firms also recently commented on ITCI. BidaskClub raised shares of Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a research report on Thursday, October 31st. Zacks Investment Research raised shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $9.50 target price for the company in a research report on Thursday, October 24th. JMP Securities set a $21.00 target price on shares of Intra-Cellular Therapies and gave the stock a “buy” rating in a research report on Tuesday, September 10th. Royal Bank of Canada set a $26.00 target price on shares of Intra-Cellular Therapies and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, Cantor Fitzgerald set a $27.00 target price on shares of Intra-Cellular Therapies and gave the stock a “buy” rating in a research report on Tuesday, September 10th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $23.19.
NASDAQ:ITCI opened at $9.57 on Friday. The company has a current ratio of 8.86, a quick ratio of 8.86 and a debt-to-equity ratio of 0.08. Intra-Cellular Therapies has a 12 month low of $6.75 and a 12 month high of $19.70. The company has a market cap of $546.77 million, a PE ratio of -3.37 and a beta of 1.18. The company has a 50 day simple moving average of $8.43 and a two-hundred day simple moving average of $10.55.
In other news, EVP Mark Neumann sold 6,774 shares of Intra-Cellular Therapies stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $8.25, for a total transaction of $55,885.50. Following the transaction, the executive vice president now owns 13,448 shares in the company, valued at approximately $110,946. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Christopher D. Alafi purchased 125,000 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were acquired at an average price of $8.52 per share, for a total transaction of $1,065,000.00. Following the purchase, the director now directly owns 341,223 shares in the company, valued at $2,907,219.96. The disclosure for this purchase can be found here. Company insiders own 18.20% of the company’s stock.
Several institutional investors have recently modified their holdings of ITCI. Quantamental Technologies LLC purchased a new position in shares of Intra-Cellular Therapies during the 2nd quarter worth $49,000. Nisa Investment Advisors LLC purchased a new position in shares of Intra-Cellular Therapies during the 3rd quarter worth $70,000. Bank of Montreal Can boosted its stake in shares of Intra-Cellular Therapies by 114.4% during the 2nd quarter. Bank of Montreal Can now owns 7,067 shares of the biopharmaceutical company’s stock worth $92,000 after acquiring an additional 3,771 shares during the last quarter. First Mercantile Trust Co. lifted its stake in shares of Intra-Cellular Therapies by 14.1% during the 2nd quarter. First Mercantile Trust Co. now owns 13,146 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 1,624 shares in the last quarter. Finally, Slow Capital Inc. purchased a new position in shares of Intra-Cellular Therapies during the 2nd quarter valued at $195,000. Institutional investors and hedge funds own 67.55% of the company’s stock.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc, a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disorders. The company is developing its lead drug candidate, lumateperone for the treatment of schizophrenia, bipolar disorder, behavioral disturbances associated with dementia, autism, and other CNS diseases.
Featured Story: Why is the LIBOR significant?
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.